Dr. Govindan on the Future of EGFR-Mutant NSCLC

Video

In Partnership With:

Ramaswamy Govindan, MD, professor, Department of Medicine, Oncology Division, Medical Oncology, Washington University School of Medicine in St. Louis, discusses the future treatment landscape of EGFR-mutant non–small cell lung cancer (NSCLC).

Ramaswamy Govindan, MD, professor, Department of Medicine, Oncology Division, Medical Oncology, Washington University School of Medicine in St. Louis, discusses the future treatment landscape of EGFR-mutant non—small cell lung cancer (NSCLC).

Clinical practice is already changing, Govindan says, as physicians are biopsying patients at the time of disease progression and obtaining cell-free DNA analyses. Moreover, second-line therapy is being decided based on gene alterations.

Secondly, Govindan explains that there is a good strategy in place for at least half of the patients who progress beyond the first-generation EGFR inhibitor. In the coming years, investigators will find a way to combine various agents and, hopefully, come up with novel agents that move downstream to work alongside EGFR inhibitors, as well.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,